The Advent of Biosimilars in Oncology: Planning Proactively for Change

About ZS

ZS is the world’s largest firm focused exclusively on helping companies improve overall performance and grow revenue and market share through end-to-end sales and marketing solutions—from customer insights and strategy, to analytics, to operations and technology. More than 4,500 ZS professionals in 22 offices worldwide draw on deep industry and domain expertise to deliver impact for clients across multiple industries.

The Advent of Biosimilars in Oncology: Planning Proactively for Change

A Panel Discussion with OBR, ZS and Industry Experts on the Changing Roles of Payers, Providers and Manufacturers
With several oncology biosimilars expected to hit the U.S. market in the next few years, pharmaceutical drug manufacturers need clear insight into stakeholder perceptions and key drivers of adoption in order to thrive in a crowded and complex marketplace. In this webinar, ZS and industry experts discuss the following:
 

Watch the Webinar

Panelists:


Christina Corridon
Christina Corridon
Associate Principal
ZS Associates
Howard Hochster, MD
Howard Hochster, MD
Professor of Medicine, Associate Director for Clinical Services
Yale Cancer Center
Steven B. Miller, MD
Steven B. Miller, MD
Senior Vice President & Chief Medical Officer
Express Scripts

Moderated By:


Don Sharpe
Don Sharpe
President
OBR